La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Century Therapeutics Bilan de santé

Santé financière contrôle des critères 6/6

Century Therapeutics possède un total de capitaux propres de $222.1M et une dette totale de $0.0, ce qui porte son ratio d'endettement à 0%. Son actif total et son passif total sont $416.4M et de $194.3M.

Informations clés

Ratio d'endettement

US$0

Dette

Ratio de couverture des intérêts	n/a
Argent liquide	US$196.40m
Fonds propres	US$222.10m
Total du passif	US$194.34m
Total des actifs	US$416.45m

Mises à jour récentes de la santé financière

Century Therapeutics (NASDAQ:IPSC) Will Have To Spend Its Cash Wisely

Mar 06

We're A Little Worried About Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate

Oct 23

Recent updates

Century Therapeutics: Cell Therapy Biotech With Expanded Potential Of CNTY-101

Jun 20

Century Therapeutics (NASDAQ:IPSC) Will Have To Spend Its Cash Wisely

Mar 06

Century Therapeutics: More Attention Doesn't Mean You Should Buy Into INK Cell Therapy

Feb 01

We're A Little Worried About Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate

Oct 23

Century Therapeutics receives IND clearance for allogeneic cell therapy candidate

Aug 25

Analyse de la situation financière

Passif à court terme: Les actifs à court terme de IPSC ( $203.5M ) dépassent ses passifs à court terme ( $19.2M ).

Passif à long terme: Les actifs à court terme de IPSC ( $203.5M ) dépassent ses passifs à long terme ( $175.2M ).

Historique et analyse du ratio d'endettement

Niveau d'endettement: IPSC est sans dette.

Réduire la dette: IPSC n'avait aucune dette il y a 5 ans.

Bilan

Analyse des pistes de trésorerie

Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.

Piste de trésorerie stable: IPSC dispose d'une piste de trésorerie suffisante pour plus d'un an sur la base de son flux de trésorerie disponible actuel.

Prévisions de trésorerie: IPSC dispose d'une marge de trésorerie suffisante pour 1.2 ans si le flux de trésorerie disponible continue de diminuer à un taux historique de 19.1 % chaque année.

Century Therapeutics Bilan de santé

Santé financière contrôle des critères 6/6

Informations clés

Mises à jour récentes de la santé financière

Century Therapeutics (NASDAQ:IPSC) Will Have To Spend Its Cash Wisely

We're A Little Worried About Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate

Recent updates

Price target decreased by 7.1% to US$11.33

Consensus revenue estimates increase by 24%

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Century Therapeutics: Cell Therapy Biotech With Expanded Potential Of CNTY-101

Century Therapeutics Presents Interim Results from Phase 1 Elipse-1 Study At Asco 2024 Annual Meeting

Price target decreased by 18% to US$12.20

Consensus revenue estimates increase by 77%

Century Therapeutics Presents Preclinical Data Highlighting Advances in Ipsc Platform Technology and Programs At 2024 Asgct Annual Meeting

First quarter 2024 earnings released: US$0.45 loss per share (vs US$0.53 loss in 1Q 2023)

Century Therapeutics, Inc., Annual General Meeting, Jun 20, 2024

Century Therapeutics, Inc. announced that it expects to receive $59.999982 million in funding from a group of investors

Century Therapeutics, Inc. (NasdaqGS:IPSC) agreed to acquire Clade Therapeutics, Inc. from Syncona Limited (LSE:SYNC) for $45 million.

Consensus revenue estimates decrease by 86%, EPS upgraded

Full year 2023 earnings released: US$2.30 loss per share (vs US$2.27 loss in FY 2022)

COO & Head of Early Development notifies of intention to sell stock

Century Therapeutics (NASDAQ:IPSC) Will Have To Spend Its Cash Wisely

Century Therapeutics: More Attention Doesn't Mean You Should Buy Into INK Cell Therapy

Century Therapeutics, Inc. Announces CFO Changes

Century Therapeutics, Inc. Announces CFO Changes

Century Therapeutics Presents Initial Data from CNTY-101 Phase 1 ELiPSE-1 Trial Supporting the Potential for A Multi-Dosing Strategy for Car iNK Enabled by Allo-Evasion Edits

Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus

New minor risk - Share price stability

Consensus revenue estimates fall by 32%

Century Therapeutics, Inc. Announces Chief Executive Officer Changes

We're A Little Worried About Century Therapeutics' (NASDAQ:IPSC) Cash Burn Rate

New major risk - Financial position

New minor risk - Market cap size

Consensus revenue estimates increase by 20%

Price target decreased by 19% to US$14.00

Consensus revenue estimates decrease by 48%, EPS upgraded

New major risk - Financial position

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Financial position

Price target decreased by 9.2% to US$17.89

Price target decreased by 8.6% to US$18.00

Chief Scientific Officer recently sold US$55k worth of stock

Chief Scientific Officer exercised options and sold US$351k worth of stock

Century Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Elipse-1 Trial Evaluating Cnty-101 in Relapsed or Refractory Cd19 Positive B-Cell Lymphomas

Price target decreased to US$20.30

Consensus revenue estimates increase by 26%

High number of new and inexperienced directors

Century Therapeutics Announces Presentation of Preclinical Data At the SITC 37Th Annual Meeting and Provides Pipeline Updates

Price target decreased to US$22.44

Casdin Capital Engages in Discussions with Century Therapeutics

Century Therapeutics, Inc. Announces Board Changes

Century Therapeutics, Inc. Receives Study May Proceed Notification from FDA for CNTY-101

Century Therapeutics receives IND clearance for allogeneic cell therapy candidate

Consensus revenue estimates fall by 20%

Century Therapeutics, Inc.(NasdaqGS:IPSC) dropped from Russell 2000 Growth Index

Consensus revenue estimates increase by 2,133%

High number of new and inexperienced directors

Century Therapeutics, Inc., Annual General Meeting, Jun 09, 2022

High number of new and inexperienced directors

Century Therapeutics Announces Presentation of Data At the 63Rd American Society of Hematology Annual Meeting and Provides Pipeline Updates

Analyse de la situation financière

Historique et analyse du ratio d'endettement

Bilan

Analyse des pistes de trésorerie

Découvrir des entreprises saines